Pros | ![]() 5Y returns in the top 25% of the category. ![]() 3Y returns in the top 25% of the category. ![]() Among most bought funds within the category. | ![]() Among most bought funds within the category. ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | ![]() 5Y returns in the bottom 25% of the category. ![]() 3Y returns in the bottom 25% of the category. |
INDMoney rank | 3/8 | 7/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 7 Years | 12 Years | ||
Fund Size | 6227 Cr | 8114 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 1.04% | 0.89% | ||
Exit Load | 1% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 43 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.58%) Dr Reddy's Laboratories Ltd (9.1%) Divi's Laboratories Ltd (8.75%) Aurobindo Pharma Ltd (8.25%) Cipla Ltd (6.92%) | Sun Pharmaceuticals Industries Ltd (12.29%) Lupin Ltd (7.26%) Divi's Laboratories Ltd (7.01%) Cipla Ltd (6.48%) Apollo Hospitals Enterprise Ltd (5.92%) | ||
No of Sectors | 3 | 1 | ||
Top 3 Sectors | Health (97.7%) Basic Materials (1.18%) Financial Services (1.12%) | Health (100%) | ||
Equity % | 97.55% | 99.47% | ||
Debt % | - | - | ||
P/E | 30.65 | 35.64 | ||
P/B | 4.17 | 5.65 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -1.22% | -1.23% | ||
3-Month Return | 0.46% | -0.91% | ||
6-Month Return | 11.61% | 6.58% | ||
1-Year Return | 4.91% | -0.26% | ||
3-Year Return | 29.27% | 23.33% | ||
5-Year Return | 21.64% | 18.91% |
Sharpe | 1.24 | 0.95 | ||
Alpha | 4.3 | -0.12 | ||
Beta | 0.95 | 0.91 | ||
Standard Deviation | 15.67 | 15.23 | ||
Information Ratio | 1.4 | -0.44 |
Description | ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Dharmesh Kakkad,Sharmila D’mello | Sailesh Raj Bhan,Kinjal Desai |